Participated · Equity · Oct 2023

Capital Rx operates a cloud-native pharmacy benefit management (PBM) platform that adjudicates prescription drug claims and provides price transparency to employers, insurers, and other payers. The company is now broadening its technology to handle medical claims as well, positioning itself as an end-to-end claims processor across both pharmacy and medical benefits. By unifying these workflows, Capital Rx aims to give payers better visibility into total healthcare spending and negotiate more favorable rates. Management says the fresh capital will accelerate product expansion and support additional hiring to meet customer demand. The firm reports an oversubscribed funding round and cites strong interest from new and existing investors. A spokesperson disclosed that Capital Rx now carries a $3.25 billion valuation, underscoring investor confidence in its growth trajectory. Although detailed revenue or user metrics were not provided, the company emphasized that the additional funds will enable it to scale its platform nationwide.

Participated · Series E · Feb 2022

Somatus operates a value-based kidney care model that combines proprietary technology, multi-disciplinary community-based care teams, and partnerships with nephrologists and primary care physicians to prevent disease progression and improve outcomes. The company delivers personalized, in-home care and support and focuses on prevention, awareness, increasing home dialysis use, and raising transplantation rates. Somatus has expanded rapidly, launching six new health plan partners in 2021, growing membership and reach, and adding more than 1,000 team members to exceed 1,350 total teammates. In 2022 the company will serve over 150,000 members across 34 states, spanning Medicare, Medicare Advantage, Medicaid, and Commercial plans. The model emphasizes lowering total cost of care through integrated, evidence-based interventions. Somatus is using recent funding to further expand its proven care model and build a nationwide network of providers and connected patients. Somatus delivers integrated, value-based kidney care using a vertically integrated clinical services model and a proprietary RenalIQ technology platform that powers field-based care teams. The company combines multiple data sets to predict undiagnosed disease, disease progression, utilization, and the likelihood of unplanned dialysis starts, and pairs that intelligence with specialized renal clinicians and community-based team members. Somatus reports serving more than 20,000 chronic kidney disease and end-stage kidney disease patients across six states and employs roughly a 300-person team. The model emphasizes evidence-based care pathways, personalized outreach, higher use of home dialysis modalities, and increased rates of kidney transplantation, and has produced quality and cost outcomes for partners. Somatus plans to scale its model nationally, expand partnerships with health plans, invest in technology and product development, and grow its workforce. The company will also release a patient-facing mobile application to help patients monitor kidney health goals, connect virtually with care teams, access micro-learning modules, and track transplant journeys. Somatus delivers longitudinal dialysis and care management services to patients on behalf of health system and payer customers. The company partners with enterprise customers to design population health strategies that mobilize disparate community-based care teams, prioritize lower-cost home-based therapies, and manage total cost of care for kidney populations. It operates a technology and service platform that supports those services. Somatus intends to use the Series B proceeds to extend the capabilities of its technology and service platform and to fund expansion into additional markets. Founded in 2016 and based in Vienna, Va., the company was co-founded by Dr. Ikenna Okezie (CEO) and Tony Welters (Chairman); Dr. Ramon Mendez serves as VP Medical Affairs. The company contracts with health systems and payers to deliver and manage kidney care.

Participated · Equity · Nov 2021

PierianDx builds assay-agnostic interpretation technology and services to help providers, laboratories, and medical centers run next-generation sequencing (NGS) testing on site. The company pairs advanced interpretation software with a comprehensive genomic knowledgebase to empower clinicians to understand genetic variation and inform treatment decisions. PierianDx partners with industry leaders and medical facilities worldwide as they build or expand precision medicine programs. The firm was founded in 2014 as a technology-transfer spinout from Washington University in St. Louis and is headquartered in St. Louis. Management says the business is expanding commercially as more healthcare organizations seek to internalize NGS testing capabilities. The recent financing is intended to fund commercial expansion and continued product and team development to bring genomics into more clinical settings. PierianDx offers a SaaS clinical genomics informatics platform that enables the practice of clinical next-generation sequencing (NGS) as a standard of care and supports advanced molecular diagnostic laboratories. The company also operates a CAP- and CLIA-accredited laboratory and provides integrated reporting and decision-support across the clinical care spectrum. PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Leadership emphasizes adding clinical expertise and resources to drive adoption of clinical NGS globally. Management plans to accelerate commercial expansion across the U.S. and international markets including Europe, Asia, Australia, and Latin America. PierianDx was founded in 2014 out of Washington University in St. Louis. PierianDx provides genomic software and services to enable data-driven personalized medicine. Its flagship platform, Clinical Genomicist Workstation (CGW), delivers data-driven workflows for health systems, academic medical centers, and commercial labs to support genomic analysis, interpretation and reporting. Led by CEO Ted Briscoe, the company focuses on improving patient outcomes through precise genomic analysis. PierianDx said it will use the new funding to accelerate product development and expand sales, marketing and operations. The company raised $9.25M in a Series A to support these initiatives.

Led · Equity · Mar 2019

Babyscripts offers a mobile clinical solution for remote monitoring in pregnancy, combining a mobile app with internet-connected devices, digital education, and customized risk-specific experiences. The platform enables providers and payers to manage patients via risk-based care modules, remote monitoring, and automated care elements. Babyscripts reports managing more than 200K unique pregnancies across 30 states and says its tools can allow providers to manage up to 90% of pregnancies virtually. The solution is delivered via a joint deployment model that incorporates payers sponsoring platform use at participating sites to identify and triage member risk and improve care coordination. The company emphasizes targeting and reducing systemic racial and ethnic inequities in maternal and infant outcomes. Babyscripts intends to use the new funding to accelerate rollout of its Virtual Maternity Care solution across U.S. providers and to develop models specifically designed for payers; the company has raised $37M to date. Babyscripts offers a virtual maternity care platform that pairs medical-device kits (blood pressure, weight, captured blood sugars) with a mobile app to monitor and alert clinicians to maternal health issues. The platform can automate roughly 40%–50% of prenatal care and has been shown to accelerate diagnoses (for example, preeclampsia detected 13 days faster than standard care at a site). Babyscripts is used by 75 health systems across 32 states and monitors about 250,000 women annually; more than 70% of its patients are on Medicaid. The company expanded product lines from a single device to multiple targeted kits and recently launched a mental health product while developing a substance use disorder experience. Babyscripts has formed partnerships with public health departments, managed Medicaid plans and providers to enable local payment and broader deployment. The company grew enrollments 10x during the pandemic and has 45 employees, with plans to double headcount in the next 12–18 months to support product, payer growth, clinical expertise, implementation and customer success. Babyscripts builds a clinically validated virtual care platform that allows OBGYNs to deliver a new model of prenatal and postpartum care using internet-connected devices for remote monitoring. The platform offers risk-specific experiences and the company says it can allow providers to manage up to 90% of pregnancies virtually. Babyscripts has spent six years developing what it describes as the most-implemented mobile clinical solution for remote monitoring in pregnancy and was named to CB Insights' 2020 Digital Health 150. The company emphasizes partnering with physicians and health systems to guide product development and improve maternal outcomes. Its stated mission is to eliminate maternal mortality and expand access to care. Recent health-system partnerships are intended to align Babyscripts' roadmap with customer needs and support scaling of its virtual maternity care solutions. Babyscripts offers a clinically-validated virtual care obstetrics platform that uses internet-connected devices for remote monitoring to support prenatal and postpartum care. The core product delivers risk-specific experiences to allow OBGYNs to manage a large portion of pregnancies remotely. The system is designed to detect risk more quickly and automate elements of care, enabling providers to manage up to 90% of pregnancies virtually. Led by CEO and co-founder Anish Sebastian, the company has spent the last four years building this platform. Babyscripts recently acquired iBirth, expanding its offering to include a provider-delivered, co-branded pregnancy app and a more holistic pregnancy and postpartum program. Financially, Babyscripts raised $500K from Inova Health System, which will support deployment of the platform. Babyscripts develops a mobile app and remote-monitoring devices that track blood pressure and weight and deliver neonatal care information to expecting mothers. The company works with hospitals and healthcare providers to distribute its devices and software, creating a channel between patients and OBGYNs throughout pregnancy. Using remote monitoring, Babyscripts says it can tailor treatments to risk profiles and enable providers to manage up to 90% of pregnancies virtually. The platform is already being used to monitor 160,000 pregnancies across 20 states, and the company reports average patient engagement of six app or monitoring interactions per week. Leadership says the company will use funding to continue acquiring market share and build additional products for pregnancy patients, including postpartum and early-stage pediatric services through expanded offerings.